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ABSTRACT  24 
Background  25 
Hashimoto’s Thyroiditis (HT) is considered to be the most common autoimmune disease. It is 26 
currently accepted that genetic susceptibility, environmental factors and immune disorders 27 
contribute to its development. Regarding nutritional factors, evidence implicates high iodine 28 
intake, deficiencies of selenium and iron with a potential relevance of vitamin D status as 29 
contributing factors. To elucidate the role of nutritional factors in the risk, pathogenesis and 30 
treatment of HT, PubMed and the Cochrane Library were searched for publications on iodine, 31 
iron, selenium and vitamin D and risk/treatment of HT. 32 
Summary 33 
Iodine: Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly 34 
because highly-iodinated thyroglobulin is more immunogenic. Recent introduction of 35 
universal salt iodization can have a similar, though transient, effect.  36 
Selenium: Selenoproteins are essential to thyroid action. In particular, the glutathione 37 
peroxidases protect the thyroid by removing excessive hydrogen peroxide produced for 38 
thyroglobulin iodination. Genetic data implicate the anti-inflammatory selenoprotein S in HT 39 
risk. There is evidence from observational studies and randomized controlled trials that 40 
selenium/selenoproteins can reduce TPO-antibody titers, hypothyroidism and postpartum 41 
thyroiditis. 42 
Iron: Iron deficiency impairs thyroid metabolism. Thyroid peroxidase (TPO), the enzyme 43 
responsible for the production of thyroid hormones is a heme (iron-containing) enzyme; it 44 
becomes active at the apical surface of thyrocytes only after binding heme. HT patients are 45 
frequently iron-deficient since autoimmune gastritis, which impairs iron absorption, is a 46 
common co-morbidity. Treatment of anemic women with impaired thyroid function with iron 47 
improves thyroid-hormone concentrations while thyroxine and iron together are more 48 
effective in improving iron status. 49 
Vitamin D: Lower vitamin D status has been found in HT patients than in controls and 50 
inverse relationships of serum vitamin D with TPO/thyroglobulin antibodies have been 51 
reported. However, other data and the lack of trial evidence suggest that low vitamin-D status 52 
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is more likely the result of autoimmune disease processes that include vitamin D-receptor 53 
dysfunction. 54 
Conclusions 55 
Clinicians should check patients’ iron- (particularly in menstruating women) and vitamin-D 56 
status to correct any deficiency. Adequate selenium intake is vital in areas of iodine-57 
deficiency/excess and in regions of low selenium intake a supplement of 50 to 100 µg/day 58 
selenium may be appropriate.  59 
 60 
 61 
62 
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INTRODUCTION 63 
Hashimoto’s Thyroiditis (HT), also known as chronic lymphocytic thyroiditis and chronic 64 
autoimmune thyroiditis, is now considered to be the most common autoimmune disease (1) 65 
and is the most common cause of primary hypothyroidism in iodine-sufficient areas (2). It 66 
includes a spectrum of histopathological and clinical entities that are collectively 67 
characterized by intrathyroidal lymphocytic infiltration (1). Currently, HT is mainly 68 
diagnosed by positive titers of serum autoantibodies against thyroid peroxidase (TPOAb) and 69 
thyroglobulin (TgAb) as well as diffuse hypoechogenicity on thyroid ultrasonography (1). 70 
Patients may present with various thyroid function states but most of them eventually evolve 71 
into hypothyroidism (1). HT patients can suffer from a variety of local and systemic 72 
manifestations accompanied by other autoimmune disorders (1). Moreover, HT has been 73 
found to be associated with an increased risk of primary thyroid lymphoma and papillary 74 
thyroid cancer (3). 75 
 76 
Although discovered a century ago, the pathogenesis of HT remains unclear. It is currently 77 
accepted that the complex interactions of genetic susceptibility, environmental factors and 78 
immune disorders contribute to its development (4). Family and twin studies have confirmed 79 
a significant genetic influence on HT susceptibility (4). However, the concordance rate for 80 
overt Hashimoto’s hypothyroidism found in Danish monozygotic twins was 55%, indicating 81 
an almost equally important role of environmental factors in the disease pathogenesis (5). A 82 
probable mechanistic model is that in genetically susceptible individuals, several 83 
environmental factors may trigger thyroid autoimmunity by increasing the immunogenicity of 84 
thyroid autoantigens, enhancing antigen presentation in the thyroid and reducing self-85 
tolerance (4). Consequently, various pro-inflammatory cytokines are produced by immune 86 
and thyroid cells, resulting in predominantly Th1 and Th17 responses with an increased 87 
Th1/Th2 ratio (4). Meanwhile, increased production of pro-apoptotic cytokines leads to 88 
thyrocyte apoptosis and finally, thyroid destruction (4). In addition, a decreased number or 89 
impaired function of regulatory T cells (Tregs), which are pivotal for maintaining peripheral 90 
tolerance and suppressing excessive immune response, has been recognized to play an 91 
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important role in the pathogenesis of HT (6). 92 
 93 
Regarding environmental factors, evidence implicates high iodine intake, selenium 94 
deficiency, infection, certain drugs and chemicals in risk, while smoking and moderate 95 
alcohol consumption have a protective effect (7, 8). Studies have also suggested a role for 96 
other common micronutrients, most notably iron and vitamin D, on HT risk (8). Although 97 
there is some evidence of an effect of vitamin A and zinc on thyroid metabolism, only sparse 98 
data are available on their relationship with HT. Hence in this review, we will concentrate on 99 
iodine, selenium, iron and vitamin D.  100 
 101 
METHODS  102 
PubMed and the Cochrane Library were searched for publications up to October 2016 using 103 
the search terms “Hashimoto’s thyroiditis” OR “autoimmune thyroiditis” OR “autoimmune 104 
thyroid disease” in combination with “iodine”, “selenium”, “iron”, “vitamin D” and 105 
“nutrition OR diet”. Articles were filtered by relevance of title, abstract and finally the full 106 
text. Relevant conclusions or results were extracted from each article.  107 
 108 
REVIEW 109 
Iodine 110 
The micronutrient, iodine, is an essential constituent of the thyroid hormones which play a 111 
pivotal role in growth, development and metabolism (9). The biologically active form, tri-112 
iodothyronine (T3), stimulates oxygen consumption, controls basal metabolic rate and 113 
thermogenesis, regulates the expression of numerous target genes that affect protein synthesis 114 
either positively or negatively, regulates cell activity and growth, and is essential for brain 115 
development and function, particularly in fetal life (9). 116 
 117 
Role of iodine in the thyroid 118 
Iodide is taken up from blood by thyroid epithelial cells. At the apical surface of the 119 
thyrocyte in the follicular lumen, in the presence of hydrogen peroxide (H2O2), the enzyme 120 
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thyroid peroxidase (TPO) iodinates tyrosine molecules on the surface of thyroglobulin, a 121 
large glycoprotein synthesized by thyroid epithelial cells (9). The products are mono- and di-122 
iodotyrosines (9). Coupling of these products, still attached to thyroglobulin, again catalyzed 123 
by TPO in the presence of H2O2, forms the thyroid hormones, T3 and thyroxine (T4) (9). The 124 
iodinated thyroglobulin molecule then enters the thyrocyte and is digested, releasing T4 and 125 
T3 into the circulation (9). 126 
 127 
Evidence for a relationship between iodine intake/status and HT risk 128 
Iodine intake has a key influence on the spectrum of thyroid disorders in populations (2, 10). 129 
Severe iodine deficiency causes goiter and hypothyroidism due to reduced production of 130 
thyroid hormone whereas chronic mild-to-moderate iodine deficiency may increase the 131 
prevalence of toxic nodular goiter and hyperthyroidism (2, 10). Excess iodine intake or a rise 132 
in intake after initiating iodine fortification of an iodine-deficient population are associated 133 
with an increased risk of subclinical hypothyroidism and thyroid autoimmunity (2, 10). 134 
 135 
Iodine deficiency has long been an important public health issue worldwide, causing multiple 136 
detrimental consequences (11). Since the implementation of iodine fortification, particularly 137 
universal salt iodization, substantial progress has been made to prevent and control iodine-138 
deficiency disorders. However, excessive iodine intake, which can also result from the 139 
implementation of universal salt iodization programs at too high a level of supplementation, 140 
increases the risk of several thyroid disorders, including autoimmune thyroiditis (12). 141 
Numerous epidemiological studies have associated high iodine intake with increased 142 
prevalence of autoimmune thyroiditis in populations (12-16). However, the optimization of 143 
nutritional iodine intake ultimately results in decreased prevalence of autoimmune thyroiditis 144 
(17). The association between high iodine exposure and increased incidence of autoimmune 145 
thyroiditis has also been demonstrated in a variety of animal models with genetic 146 
susceptibility (18-20). The ingestion of excess iodide through drinking water by the 147 
autoimmune thyroiditis-prone NOD.H2h4 mouse significantly enhances and accelerates the 148 
incidence and severity of autoimmune thyroiditis in a dose-dependent manner (21). 149 
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 150 
The mechanisms by which increased chronic intake of dietary iodine induces autoimmune 151 
thyroiditis are unclear. It is thought that in genetically susceptible individuals, chronic high 152 
iodine exposure may: (i) increase the immunogenicity of thyroglobulin, (ii) induce auto-153 
antigen presentation activity of thyrocytes and dentritic cells, (iii) impair peripheral tolerance 154 
by inhibiting Tregs, (iv) cause oxidative stress leading to thyroid tissue injury, (v) activate 155 
auto-reactive T cells which increases cytokine secretion and eventually triggers apoptosis-156 
signaling pathways, leading to thyroid destruction (12, 21, 22).  157 
 158 
Recommendations on iodine intake 159 
The level of dietary iodine intake has a very significant effect on the pattern of thyroid 160 
disorders in populations. While iodine deficiency is recognized to have multiple adverse 161 
effects on the thyroid, with regard to autoimmune thyroiditis/HT, there is more evidence for 162 
an association with iodine excess, especially in genetically susceptible individuals (12, 16, 163 
22). To avoid an increased risk of HT, it is therefore important to ensure, as far as possible, 164 
that iodine intake falls within a relatively narrow range of the recommended levels (23) [see 165 
Table 1 (24-26)]. On a population basis, this would be represented by a median urinary iodine 166 
concentration in adults of 100-200 µg/l (26). Authorities introducing iodine fortification of 167 
the food supply in a country (e.g. universal salt iodization) need to ensure that such 168 
fortification is introduced very cautiously; Denmark provides an excellent example of how 169 
this can be done (27). 170 
 171 
Selenium 172 
Selenium is a trace mineral essential for human health (28). As selenocysteine (an analogue 173 
of cysteine), it is incorporated into 25 human selenoproteins that have a wide range of 174 
functions ranging from antioxidant and anti-inflammatory agents to the production of active 175 
thyroid hormone (28, 29). An indication of the importance of selenium to the thyroid is the 176 
fact that it contains the highest concentration of selenium in the human body and is able to 177 
retain that selenium under conditions of severe deficiency that cause its loss from many other 178 
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tissues (30).  179 
 180 
Role of selenium in the thyroid: selenoproteins  181 
A number of selenoproteins are expressed in thyrocytes, e.g. the deiodinase isozymes (Dio1, 182 
Dio2, though not Dio3), members of the glutathione peroxidase family (GPx1, GPx3, GPx4), 183 
the thioredoxin reductases (TxnRd1 and TxnRd2), selenoprotein 15, selenoprotein P 184 
(SELENOP), and selenoproteins M and S (SELENOM, SELENOS) (31). Those below play 185 
particularly important roles.  186 
The deiodinases (DIO): DIO1 and DIO2 can activate T4 by transforming it into T3 by 187 
removal of the 5ʹ-iodine, while DIO1 and DIO3 can prevent T4 from being activated by 188 
converting it to the inactive reverse T3 (32). DIO3 can also inactivate T3 by 5-deiodination to 189 
T2. Outside the thyroid, DIO2 is largely responsible for local conversion of T4 to T3 in target 190 
tissues (29). DIO3 is found in fetal tissue, the placenta and central nervous system where it 191 
protects sensitive cells from thyrotoxic concentrations of active T3 (29, 33). 192 
The glutathione peroxidases (GPx): GPx3, normally found in the plasma is also secreted at 193 
the apical side of the thyrocyte membrane where it degrades excess H2O2 that has not been 194 
used by TPO for the iodination of tyrosyl residues of thyroglobulin or for iodotyrosine 195 
coupling (34) (see Figure 1). GPx-1 protects the intracellular compartment from excessive 196 
H2O2 that may diffuse into the thyrocytes while GPx4 can remove excessive lipid 197 
hydroperoxides in the mitochondria (33, 34).  198 
Selenoprotein S (SELENOS): SELENOS is involved in the control of the inflammatory 199 
response in the endoplasmic reticulum (ER) (35). In a Portuguese study, the SELENOS 200 
−105G/A promoter polymorphism (rs28665122) was strongly associated with circulating 201 
levels of cytokines such as IL-1β, IL-6 and TNF-α (36), that are known to be involved in HT 202 
pathogenesis. A-allele carriers of this polymorphism were more than twice as likely as GG-203 
homozygotes to have HT; in male carriers, the risk was four-fold higher (36). 204 
 205 
Evidence for a relationship between selenium intake/status and HT risk/treatment 206 
Deficiency of selenium has been associated with a number of adverse thyroid conditions, 207 
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including hypothyroidism, subclinical hypothyroidism and autoimmune thyroiditis/HT (37), 208 
an enlarged thyroid (37-39); thyroid cancer (31, 40, 41); and Graves’ disease (42). 209 
 210 
A recent study, very relevant to the effect of selenium status on HT risk, was carried out in 211 
two counties of Shaanxi Province, China, that had high genetic, environmental and lifestyle 212 
similarities, and comparable iodine status, but very different selenium status – adequate and 213 
low (37). Participants (n=6152) completed demographic and dietary questionnaires, 214 
underwent physical and thyroid-ultrasound examinations and had serum samples analyzed for 215 
thyroid-function parameters and selenium concentration. Median (IQR) selenium 216 
concentrations differed almost two-fold [103.6 (79.7, 135.9) vs. 57.4 (39.4, 82.1) μg/L; 217 
P=0.001] between participants from the two counties. After adjustment for potential 218 
confounders, the prevalence of pathological thyroid conditions was significantly lower in the 219 
adequate-selenium than in the low-selenium county (18.0% vs. 30.5%; P<0.001). Higher 220 
serum selenium was associated with lower odds [OR (95% CI)] of autoimmune thyroiditis 221 
[0.47 (0.35, 0.65)], hypothyroidism [0.75 (0.63, 0.90)], subclinical hypothyroidism [0.68 222 
(0.58, 0.93)], and enlarged thyroid [0.75 (0.59, 0.97)] (37). Both these counties had an iodine 223 
intake that was more-than-adequate (26, 37, 43) which may have accounted to some extent 224 
for the high level of thyroid disease prevalence (15, 44). This study suggests that in such a 225 
situation, having an adequate selenium status may be protective. 226 
 227 
Several trials of selenium supplementation have been carried out in both autoimmune 228 
thyroiditis (HT) and mild Graves' orbitopathy. In a large, multicenter, randomized, controlled 229 
trial (RCT) with selenium, patients with mild Graves’ orbitopathy significantly improved 230 
(45). There have been a number of systematic reviews/meta-analyses of controlled trials of 231 
selenium treatment in patients with autoimmune thyroiditis/HT (33, 46-48). The most recent 232 
included 16 trials in a meta-analysis that found that selenium supplementation reduced serum 233 
TPO-Ab levels after 3, 6 and 12 months in a population with chronic autoimmune thyroiditis 234 
treated with levothyroxine, and after three months in an untreated population (46). Some of 235 
these studies also saw a reduction in Tg-Ab titers at 12 months, an improvement in thyroid 236 
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echogenicity, and an increase in subjective well-being. However, the methodology of many of 237 
the studies was flawed; e.g., they were underpowered, not double-blinded, not placebo-238 
controlled, and disparities in iodine intake were not considered (46, 47, 49). The beneficial 239 
effect in some studies and not in others cannot easily be explained on the basis of baseline 240 
selenium status, stage of disease, baseline TPO-Ab titers, form or dose of selenium used (8). 241 
Hence, we still need well designed, properly powered, RCTs of selenium in the treatment of 242 
autoimmune thyroiditis/HT before we can confidently recommend selenium supplementation 243 
in HT patients.   244 
 245 
Despite these caveats, there is a rationale for a beneficial effect of selenium – probably 246 
through its role within selenoproteins – on autoimmune thyroid disease/HT: (i) selenium, as 247 
the glutathione peroxidases and the thioredoxin reductases has an antioxidant, protective 248 
function (28, 50); (ii) selenium can up-regulate regulatory T-cells resulting in increased 249 
immune tolerance (in an autoimmune thyroiditis model system) (51); (iii) selenium has anti-250 
inflammatory effects (35, 52, 53); and (iv) selenium may suppress the expression of HLA-DR 251 
molecules on thyrocytes, reducing the development of thyroid autoimmunity (50, 54).  252 
 253 
Evidence for a relationship between intake/status of selenium and autoimmune thyroid 254 
disease in pregnancy and the postpartum period 255 
Several clinico-pathologic variants are now thought to be included under the term HT, 256 
including postpartum thyroiditis (1). Pregnant women positive for TPO-Abs are likely to 257 
develop hypothyroxinemia during pregnancy and postpartum thyroiditis in the year after 258 
delivery (55). Up to 50% of TPO-Ab-positive pregnant women develop postpartum 259 
thyroiditis of whom 20-40% subsequently become hypothyroid (55). 260 
 261 
An RCT in TPO-Ab-positive women in Italy found that selenium supplementation reduced 262 
thyroid inflammatory activity and the risk of postpartum thyroid disease (56). During 263 
pregnancy and the postpartum period, 151 TPO-Ab-positive women were randomized to 264 
selenium (200 g/d as selenomethionine) or placebo. TPO-Abs fell significantly during 265 
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gestation but the reduction was significantly greater in the selenium-supplemented group 266 
(P=0.01) and remained so in the postpartum period (P=0.01) (see Figure 2). Importantly, 267 
there was a significant reduction in the incidence of postpartum thyroid disease and 268 
hypothyroidism in the selenium-supplemented group (28.6% vs. 48.6%, P<0.01 and 11.7% 269 
vs. 20.3%, P<0.01, respectively) (56). Furthermore, during treatment, women on selenium 270 
maintained the same level of ultra-sound echogenicicity whereas in those on placebo, 271 
echogenicity significantly worsened. At the end of the postpartum period, grade 2-3 272 
thyroiditis had developed in 44.3% of women on placebo but only in 27.3% of women on 273 
selenium (P<0.01). 274 
 275 
The only other RCT that investigated the effect of selenium supplementation on autoimmune 276 
thyroid disease in pregnancy found no difference in the magnitude of decrease between 277 
selenium and placebo groups (57). However the trial was underpowered, the median baseline 278 
TPO-Ab concentrations in the women were much lower than in the study by Negro et al. 279 
(56), and the selenium dose given was considerably less, i.e. 60 vs. 200 μg/d. There is clearly 280 
a need for a further, high-quality, adequately powered RCT in the TPO-Ab-positive pregnant 281 
population to see if the results of Negro and colleagues can be replicated (56). 282 
 283 
Is selenium intake/status adequate? 284 
The intake of selenium shows tremendous variability from one part of the world to another, 285 
ranging from deficient (7 g/d) to toxic (4990 g/d) levels (28). Figure 3 shows the 286 
variability and gives an indication of the level of intake believed to be needed to optimize the 287 
activity of GPx3 (58), the main selenoenzyme responsible for removing excess H2O2 from the 288 
thyroid. This geographical variability in intake (and hence, status) relates not only to the 289 
selenium content of the soil on which crops and fodder are grown, but to many other factors 290 
that determine the availability of selenium to the food chain such as selenium speciation, soil 291 
pH and organic-matter content. Mean intake is some 40 g/d in Europe and 93 (females) to 292 
134 (males) g/d in the USA (28). Recommended selenium intake varies by authority and 293 
averages 60 g/d for men and 53 g/d for women (59). Supplements of selenium contribute 294 
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to intake and are quite commonly consumed, particularly in the US, where some 50% of the 295 
population takes dietary supplements (60). 296 
 297 
Food sources of Selenium 298 
Brazil nuts are the richest food source of selenium though they are generally not a commonly 299 
eaten food, and in any case cannot be recommended as a main selenium source as the content 300 
is very variable, ranging from 0.03 to 512 mg/kg fresh weight, and they are high in barium 301 
(59). Organ meats and seafoods are good sources, followed by muscle meats, cereals and 302 
grains, though the selenium content of the latter varies widely (see Figure 4) (28, 59). Thus, 303 
in the USA, grains such as wheat are excellent selenium sources and provide some 37% of 304 
dietary Se (61) whereas in the UK, they only provide 26% of Se intake (62). 305 
 306 
Recommendations for selenium intake 307 
Though we lack evidence that selenium supplementation results in clinical improvement in 308 
autoimmune thyroiditis (other than in mild Graves’ orbitopathy), it still makes sense to ensure 309 
that selenium intake is adequate, given the roles played by selenium/selenoproteins in human 310 
health (28) and particularly in the thyroid. Regions of deficient, more-than-adequate or high 311 
iodine intake may have more need for selenium owing to the capacity of selenoproteins to 312 
protect the thyroid from damage from H2O2, reactive oxygen species and inflammation and to 313 
increase immune tolerance (see above). Hence, under these circumstances, clinicians need to 314 
be especially vigilant to ensure that selenium intake/status is adequate. Women are at greater 315 
risk of thyroid disorders and may thus have a higher requirement for additional selenium, 316 
particularly in pregnancy. In addition, geographical location will give a good indication of 317 
selenium adequacy or otherwise (see Figure 3). It is also important to enquire into the dietary 318 
habits of a given patient and see if he/she eats foods that supply selenium (see above) (28). In 319 
China, for instance, selenium-enriched tea is an excellent selenium source (37) and is 320 
available in many areas.  321 
 322 
If there appear to be few, or no, selenium-rich sources in a patient’s diet, low-dose 323 
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supplementation (50-100 µg selenium/d) is suggested. Multi-vitamin/mineral tablets may 324 
contain 50 µg selenium/d, an amount that will generally be adequate for women. A dose of 325 
100 µg selenium/d (as selenium-yeast) given to someone in the UK will raise plasma 326 
selenium to around 140 µg/L which is more than enough to optimize the synthesis of all the 327 
selenoproteins (63). Either selenium-yeast (which behaves in the body like wheat-selenium) 328 
or sodium selenite (the latter is not non-specifically incorporated into body proteins in place 329 
of methionine) is adequate (59). 330 
 331 
Even if patient with HT is being treated with levothyroxine, one needs to be aware that some 332 
studies found that giving Se as well as levothyroxine resulted in a greater reduction in TPO-333 
Abs, inflammatory cytokines and C-reactive protein (53, 64). 334 
 335 
It is also of importance to bear in mind that though selenium is essential, excessive intake of 336 
selenium is toxic and supplements of selenium of 200 µg/d, generally considered to be quite 337 
safe, have been associated with toxic effects (alopecia, dermatitis, squamous cell carcinoma, 338 
type-2 diabetes mellitus) in North American men (65-67), though these men a had higher 339 
selenium status than European men. As for many nutrients, there is a U-shaped relationship 340 
between selenium status and disease risk; therefore, it is recommended to aim for an adequate 341 
intake that does not stray into levels associated with potential toxicity (28). 342 
 343 
Iron 344 
Iron is an essential major mineral; through its presence in hemoglobin, myoglobin and many 345 
iron-containing enzymes, it is involved in a great number of metabolic processes in the body. 346 
These include oxygen transport and storage, DNA synthesis, ATP generation, oxidation-347 
reduction reactions, electron transfer and regulation of the cell cycle (68-70). In healthy 348 
adults, iron metabolism is strictly regulated to maintain body iron content within a restricted 349 
range. This is because iron deficiency leads to decreased oxygen transport and impaired 350 
activity of iron-containing enzymes, and because iron excess may predispose to iron-overload 351 
diseases and cancer (68, 69). 352 
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 353 
Role of iron in the thyroid 354 
TPO, the enzyme required for the organification and coupling reactions in thyroid hormone 355 
synthesis (71, 72) becomes active at the apical surface of thyrocytes only after it binds a 356 
prosthetic heme I group (73). Hence an adequate iron status is essential for the production of 357 
the thyroid hormones, T3 and T4.    358 
 359 
Evidence for a relationship between iron intake/status and HT risk/treatment 360 
Hashimoto’s Thyroiditis and iron deficiency 361 
Studies have revealed that HT patients with subclinical hypothyroidism have lower serum 362 
iron concentrations and a higher prevalence of iron deficiency than healthy controls (74, 75). 363 
As an organ-specific autoimmune disease, HT is frequently associated with other 364 
autoimmune disorders. Indeed, a considerable proportion of HT patients have celiac disease 365 
(76-78) or autoimmune gastritis co-morbidity (79-82) and these co-morbid conditions are 366 
regarded as the major cause of iron deficiency in HT patients. Iron-deficiency anemia is the 367 
most common extra-intestinal manifestation of celiac disease, which impairs iron absorption 368 
and leads to iron deficiency (83). Autoimmune gastritis is characterized by serum anti-369 
parietal cell antibodies and anti-intrinsic factor antibodies; it can finally evolve to severe 370 
atrophic gastritis with subsequent hypochlorhydria and chronic iron deficiency (84). Because 371 
of the abnormal gastric secretion and low acidity, dietary non-heme iron cannot effectively be 372 
solubilized leading to iron malabsorption (85).  373 
 374 
It appears likely, however, that hypothyroidism per se, which is common in HT patients, 375 
impairs gastrointestinal iron absorption. Early experiments in hypothyroid rats showed 376 
diminished gastrointestinal iron absorption that was restored to normal on supplementation 377 
with T3 (86). In two studies in patients with coexisting iron-deficiency anemia and 378 
subclinical hypothyroidism, treatment with iron and T4 together was considerably more 379 
effective in improving iron status than treatment with iron alone (87, 88).  380 
 381 
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Iron deficiency affects thyroid metabolism 382 
Not only do HT patients have a higher prevalence of iron deficiency, but iron deficiency 383 
impairs thyroid metabolism. It reduces thyroid hormone production by decreasing the activity 384 
of the iron-dependent enzyme, TPO (71-73). In rodent studies, iron deficiency, with or 385 
without anemia, decreased serum T4 and T3 concentrations, lowered 5ꞌ-deiodinase activity, 386 
and reduced the ability to thermoregulate in response to a cold environment (72, 89-91). 387 
Apart from the observed effect of iron deficiency on thyroid hormone production (72, 73), it 388 
has been suggested that it may lead to functional hypothyroidism by altering the central 389 
regulation of the thyroid axis (90) and hampering the binding of T3 to hepatic nuclear 390 
receptors (92).  391 
 392 
Human studies have provided equivocal outcomes. While a few studies found no significant 393 
association between serum thyroid hormone concentrations and iron status (93, 94), others 394 
had different results. Lower serum T4 and/or T3 and higher TSH levels were reported in 395 
women with iron-deficiency anemia than in non-anemic controls, and iron supplementation 396 
partially normalized plasma thyroid hormone concentrations (95, 96). A small Finnish study 397 
illustrates that low iron stores may contribute to symptom persistence in patients treated for 398 
hypothyroidism (97). Twenty-five women with persistent symptoms of hypothyroidism 399 
despite appropriate levothyroxine therapy became symptom-free when treated with oral iron 400 
supplements for 6-12 months. None of the women had anemia or red-cell indices outside the 401 
reference range though all had serum ferritin < 60 mg/L(97). A study conducted in 4392 402 
women of childbearing age indicated that iron deficiency was independently correlated with 403 
isolated hypothyroxinemia in both pregnant and non-pregnant women (98). Two cross-404 
sectional studies showed significantly higher risks of goiter in children with low serum iron 405 
(99, 100). 406 
 407 
Recommendations for iron intake 408 
As explained above, HT patients have a high prevalence of iron deficiency or low iron stores 409 
that may impair thyroid metabolism. Hence, we recommend routine screening of HT patients 410 
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for iron deficiency. If either deficiency or a serum ferritin < 70 µg/L is found (97), co-morbid 411 
celiac disease or autoimmune gastritis should be suspected as a potential cause and treated if 412 
necessary. If celiac disease is diagnosed, it should be formally documented. Hematological 413 
tests can be used to distinguish between iron-deficiency anemia that will respond to iron 414 
supplementation and the anemia of chronic disease that will not. Assuming the latter is not 415 
involved, supplementation to restore iron sufficiency should be instituted and will help 416 
prevent the deleterious effects of iron deficiency on thyroid function (95, 96). There are 417 
alternative supplements to ferrous sulfate (e.g. ferrous bisglycinate) that may be better 418 
tolerated by the gastro-intestinal tract (101, 102).  419 
 420 
Vitamin D 421 
Vitamin D is a steroid hormone precursor, pivotal for bone and mineral homeostasis that 422 
balances serum levels of calcium and phosphorus (103). It has two major forms of which 423 
vitamin D2 comes exclusively from diet and vitamin D3 is largely synthesized in the human 424 
skin through sunlight exposure. Despite the difference in side-chain structure, both are 425 
hydroxylated in the liver by 25-hydroxylase to 25-hydroxyvitamin D [25(OH)D, calcidiol], 426 
which is carried by vitamin D binding protein (VDBP) and is used as the circulating indicator 427 
of vitamin D status (104). In the classic pathway, 25(OH)D is then converted to 1α,25-428 
dihydroxyvitamin D [1α,25(OH)2D, calcitriol] by a cytochrome P450 enzyme, 1-α-429 
hydroxylase (CYP27B1) in the kidney; this is the hormonally active form and exerts its 430 
endocrine effects by binding to the vitamin D receptor (VDR) and regulating VDR-431 
responsive genes (105). However, numerous recent studies have shown that many tissues 432 
have local 1-α-hydroxylase that can produce 1α-25(OH)2D that has both autocrine and 433 
paracrine effects (103, 106). Moreover, the discovery of VDRs  in more than 35 tissues 434 
unrelated to bone metabolism demonstrates the pleiotropic effects of vitamin D (107). In fact, 435 
many observational studies have demonstrated inverse correlations between circulating 436 
25(OH)D concentrations and the risk of extra-skeletal diseases (108-110). 437 
 438 
Role of vitamin D in the thyroid 439 
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If vitamin D has a role in the thyroid, it is likely to be via its effect on the immune system and 440 
its role in dealing with infection. The potential for chronic infectious agents to be a causal 441 
factor for autoimmune disease has long been recognized (111). For instance, Epstein-Barr 442 
virus (EBV) is a ubiquitous herpes virus that is suspected to be involved in the pathogenesis 443 
of many autoimmune diseases (112). There is also some serological evidence of bacterial 444 
infection in patients with HT (113-115).  445 
Multiple in vitro studies have provided compelling evidence that 1α,25(OH)2D, acting 446 
through the VDR, induces innate antimicrobial activity by regulating the expression of 447 
antimicrobial peptides (cathelicidin hCAP18 and defensin beta 4) that are responsible for 448 
extensive antimicrobial action (116-119) and the activation of antibacterial autophagy (120, 449 
121). While 1α,25(OH)2D is a promoter of innate immunity, it suppresses the adaptive 450 
immune response (116) by inhibiting the pro-inflammatory effects of Th1 and Th17 cells and 451 
enhancing the anti-inflammatory activities of Th2 and Treg cells (122-124). 1α,25(OH)2D is 452 
believed to play a protective role against autoimmunity; on the one hand, it exerts special 453 
immunoregulatory and tolerogenic effects by hampering the maturation and autoantigen 454 
presentation of many dendritic-cell subsets (125), on the other, it increases the count of CD8+ 455 
T cells that are capable of controlling EBV infection and clearing EBV-infected autoreactive 456 
B cells (112).  457 
 458 
Evidence for a relationship between intake/status of vitamin D and HT risk/treatment 459 
Since excessive activation of Th1 and Th17 cells, as well as impaired function of Treg cells 460 
(6) and deficiency of CD8+ T cells (112) are implicated in the pathogenesis of HT, it is 461 
conceivable that vitamin D status may affect the development of this disorder.  462 
 463 
Evidence from animal studies 464 
In vivo studies showed that a low-dose combination of 1α,25(OH)2D3 and cyclosporine could 465 
effectively prevent the induction of experimental autoimmune thyroiditis (EAT) in an mouse 466 
model of thyroiditis similar to human Hashimoto’s thyroiditis (126). Injection of high-dose 467 
1α,25(OH)2D3 showed a therapeutic effect in established EAT rat models by improving 468 
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thyroid-gland structure and restoring Th1/Th2 cytokine equilibrium (127).  469 
 470 
Evidence from human studies 471 
Evidence from human studies is not strong; almost all studies were cross-sectional in nature 472 
and there are no randomized, controlled trials of vitamin D and thyroid autoimmunity.  473 
A number of case-control studies (128-137) reported lower mean levels of 25(OH)D as well 474 
as higher rates of vitamin D deficiency or insufficiency in HT patients than in healthy 475 
controls (see Table 2). Furthermore, subjects with vitamin D deficiency had a higher risk of 476 
developing HT than those with normal levels, e.g. for every 5 nmol/L increase in plasma 477 
25(OH)D concentration, a 1.62-times decrease in HT risk was found (129). Moreover, inverse 478 
relationships of serum 25(OH)D concentrations with TPO-Ab and Tg-Ab titers in HT patients 479 
have been seen in a number of studies (130, 132, 133, 135, 136). With regard to thyroid 480 
function, data from a case-control study demonstrated that serum 25(OH)D status correlated 481 
inversely with thyroid-stimulating hormone (TSH) levels and positively with T3 levels in 482 
hypothyroid patients (134) while hypothyroidism at diagnosis was more prevalent in HT 483 
patients with serum 25(OH)D concentrations below 10 ng/ml (25 nmol/L) than in those 484 
within the normal range (138). In a comparison of chronic and new-onset HT patients and 485 
healthy controls, a clear association was found between the severity of vitamin D deficiency 486 
and disease duration, as well as a positive correlation between serum 25(OH)D levels and 487 
thyroid-gland volume in the patients (133). 488 
 489 
However, two studies had different findings. In a case-control study, serum 25(OH)D 490 
concentration was found to be no lower in HT patients than in controls (139). More 491 
significantly, a longitudinal study failed to show lower vitamin D levels in women who 492 
developed TPO-Abs during follow-up than in those who remained thyroid-antibody negative, 493 
indicating a lack of relationship between early-stage thyroid autoimmunity and vitamin D 494 
insufficiency (140). Some of the divergence between study results might be attributable to 495 
differences in latitude, season, sunlight exposure, ethnicity, body-mass index, assay methods 496 
as well as inadequate matching between cases and controls with respect to confounding 497 
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factors that can affect vitamin D levels (139, 141, 142).  498 
 499 
Could the association between low vitamin D status and HT be a result of ill health? 500 
However, a more likely scenario may be that low concentrations of 25(OH)D in HT patients 501 
are simply a result of disease; for instance, in HT, increased body-fat mass due to 502 
hypothyroidism as well as other co-morbid autoimmune diseases may predispose to vitamin 503 
D deficiency (143). Low serum concentrations of 25(OH)D have been observed in many 504 
extra-skeletal diseases and may simply be a sign of ill-health (144). The validity of this 505 
hypothesis is strengthened by the fact that none of the numerous randomized trials carried out 506 
with vitamin D (though none was in HT) confirmed the health benefits of increased 507 
25(OH)D, even when high doses of supplementation were given to participants with low 508 
vitamin D status prior to randomization (144, 145).  509 
 510 
Could the association between low vitamin D status and HT be a result of vitamin D 511 
receptor (VDR) dysfunction? 512 
Another explanation for the low serum 25(OH)D observed in autoimmune diseases, including 513 
HT, is VDR dysfunction in phagocytes resulting from chronic infection with intracellular 514 
bacteria that dysregulate vitamin D metabolism (111). Because the VDR controls expression 515 
of the cathelicidin and beta-defensin antimicrobial peptides, dysregulation of the receptor 516 
greatly compromises the innate immune response (113). Bacterial-induced VDR dysfunction 517 
can explain the low concentrations of 25(OH)D and high concentrations of 1,25(OH)2D 518 
(111). Thus, in inflammatory conditions, unregulated extra-renal production of 1,25(OH)2D 519 
occurs and escapes breakdown by binding to the pregnane X nuclear receptor (PXR), thus 520 
inhibiting the activity of the deactivating enzyme, 24-hyroxylase (CYP24A1), which would 521 
normally degrade it to a mono-hydroxy vitamin D [e.g. 25(OH)D] (111, 114). The end effect 522 
of this VDR dysfunction is lowered 25(OH)D, implying low vitamin D status as usually 523 
measured, and elevated 1,25(OH)2D (though this is seldom measured). In other words, the 524 
low level of 25(OH)D observed in autoimmune disease is the result of the autoimmune 525 
disease process rather than its cause (113). In support of this explanation, there is evidence 526 
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that some autoimmune diseases can be reversed by gradually restoring VDR function with 527 
the administration of a VDR agonist, olmesartan, in conjunction with bacteriostatic 528 
antibiotics (111). Eight of nine genetic studies have implicated SNPs of both the VDR or 1-529 
alpha-hydroxylase genes in HT risk, though results are not wholly consistent [(partly 530 
reviewed in (146) and see Supplemental Table 1].  531 
 532 
Is vitamin D status adequate? 533 
A review of six different geographical regions has demonstrated that vitamin D deficiency is 534 
widespread across the world (147). Although both the Institute of Medicine (148) and the 535 
European Food Safety Authority (EFSA) (149) consider that a dietary intake that achieves a 536 
serum 25(OH)D concentration of 50 nmol/L is sufficient, a number of organizations prefer to 537 
define sufficiency as the higher value of 75 nmol/L, values between 75 and 50 nmol/L as 538 
insufficient and those below 50 nmol/L as deficient (141). In most of the studies that have 539 
investigated the relationship between vitamin D and autoimmune thyroid disease, vitamin D 540 
deficiency has been defined as a serum 25(OH)D concentration less than 50 nmol/L (20 541 
ng/ml). There are no available data on the optimal vitamin D concentration that can support 542 
diverse tissue responses, though it appears likely that local tissue levels need to be higher 543 
than typical serum levels (139). Locally synthesized 1α,25(OH)2D3 has been shown to be 544 
degraded immediately after its autocrine action without entering the circulation, hence even 545 
measurements of serum 1α,25(OH)2D3 may not be meaningful (139). 546 
 547 
Recommendations for vitamin D 548 
It appears highly questionable that the low serum/plasma 25(OH)D concentration in HT 549 
patients is a true reflection of a deficient vitamin D status, let alone that vitamin D deficiency 550 
is a cause of HT. Studies need to measure serum/plasma concentrations of not only 25(OH)D 551 
but of 1,25(OH)2D and indeed of 24,25(OH)2D, to get a clearer picture. Even then, the 552 
concentrations in thyroid and immune cells will not necessarily be revealed. Trials are needed 553 
to elucidate the association between vitamin D and HT so that clear evidence-based 554 
suggestions can be made. In the meantime, however, it would be wise to ensure that patients 555 
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avoid overt vitamin D deficiency. 556 
 557 
However, be aware that at high levels (e.g. achieved from supplementation), 1,25(OH)2D 558 
may have the potential to displace the natural ligands from nuclear receptors such as the α- 559 
and β-thyroid hormone receptors (111, 113). If T3 is indeed displaced from the thyroid 560 
hormone receptors, there may be adverse effects on the endocrine system. New data also 561 
show that the greater the increase in 25(OH)D on supplementation, the greater the conversion 562 
to the inactive 24,25(OH)2D, resulting in a null effect (150). 563 
 564 
Conclusions 565 
HT affects more people than any other autoimmune condition. Hence, awareness of the 566 
nutritional factors discussed above that can interact to alter the risk, progression or 567 
development of HT or associated conditions can provide an additional strategy in the hands 568 
of concerned clinicians to the benefit of a large number of patients.   569 
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Table 1. Iodine intake requirements by life stage according to various authorities 951 
 952 
Age EFSA AI 
(µg/d) (24) 
USA RDA  
(µg/d) (25) 
ICCIDD/UNICEF/WHO RNI 
(µg/d) (26) 
0-6 mth - 110 (AI) 90 
7-12 mth 70 130 (AI) 90 
1-6 yr 90 90 90 
7-10 yr  90 90-120 120 
11-14 yr  120 120-150 120-150 
15-17 yr 130 - - 
15-50 yr - 150 150 
≥ 18 yr 150 - - 
Pregnancy 200 220 250 
Lactation 200 290 250 
Abbreviations: AI, Adequate Intake; RDA, Recommended Dietary Allowance; RNI 953 
Recommended Nutrient Intake.  954 
 955 
 956 
 957 
 958 
 959 
 960 
 961 
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Table 2. Case-control studies of the association between vitamin D status and HT risk 962 
 963 
    Abbreviations: AITD, Autoimmune Thyroid Disease; GD, Graves’ Disease; HT, Hashimoto’s Thyroiditis. 964 
Author & 
reference 
Year  Country  Participants  Time of 
Sampling 
Main Indices  Significance 
Evliyaoglu et 
al. (128) 
2015  Turkey  90 HT patients and 79 healthy controls    Not specified  Vit D deficiency rate 
25(OH)D concentration 
P = 0.025   
P = 0.001 
Ma et al. 
(129) 
2015  China  70 newly diagnosed HT patients and 70 
controls 
Winter  25(OH)D concentration 
 
P < 0.001 
Shin et al. 
(130) 
2014  Korea  111 AITD patients and 193 non‐AITD patients    Throughout the 
year 
25(OH)D concentration 
 
P < 0.001 
Mansournia 
et al. (131) 
2014  Iran  41 hypothyroid HT patients and 45 euthyroid 
controls 
Autumn  25(OH)D concentration 
 
P = 0.008 
Unal et al. 
(132) 
2014  Turkey  254 newly diagnosed HT patients and 124 
healthy controls 
Not specified 
 
25(OH)D concentration 
 
P < 0.001 
 
Bozkurt et al. 
(133) 
2013  Turkey  180 chronic HT patients, 180 newly onset HT 
patients, and 180 healthy controls 
Not specified 
 
25(OH)D concentration 
Severe vit D deficiency 
rate (<10 ng/mL) 
P = 0.002 
P < 0.001 
 
Mackawy et 
al. (134) 
2013  KSA  30 hypothyroid patients and 30 healthy 
controls 
Autumn, Winter 
and Spring 
25(OH)D concentration 
   
P = 0.000 
Camurdan et 
al. (135) 
2012  Turkey  78 recently diagnosed children HT patients 
and 74 controls   
Not specified 
 
25(OH)D concentration 
Vit D deficiency rate   
P < 0.001   
P < 0.0001 
Kivity et al. 
(136) 
2011  Hungary  50 AITD patients (28 HT, 22 GD), 42 non‐AITD 
patients and 98 healthy controls 
Spring  Vit D deficiency rate 
TPOAb‐positive rate 
P < 0.001   
P < 0.001   
Tamer et al. 
(137) 
2011  Turkey  161 HT patients and 162 healthy controls  Not specified  Vit D insufficiency rate 
 
P < 0.0001 
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Figure legends 965 
Figure 1. GPXs catalyse the removal of H2O2 (and lipid hydroperoxides) converting it to 966 
harmless water thus protecting the thyroid from excessive exposure to H2O2 967 
 968 
Figure 2. Selenium protects against post-partum autoimmune thyroid disease [adapted from 969 
(56) with permission]  970 
Figure 3. Mean selenium intake levels (g/d) in different countries and the range of Se intake 971 
(55-75 g/d) believed to be required for optimal activity of plasma GPX (GPX3) [adapted 972 
from (58)] 973 
Figure 4. Typical selenium content of food sources, adapted from WHO. Selenium. A report 974 
of the International Programme on Chemical Safety. Environmental Health Criteria number 975 
58. Geneva: WHO, 1987 (reproduced from 28).  976 
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Supplemental Table 1. Case-control studies of the association between polymorphisms of the VDR and CYP27B1 genes and HT risk 982 
 983 
 984 
Abbreviations: VDR, vitamin D receptor; CYP27B1, vitamin D activating enzyme, 1-α-hydroxylase; HT, Hashimoto’s Thyroiditis; NS, Not Significant; 985 
Pc=Permutation-corrected P-value (corrected for multiple testing); SNP=Single Nucleotide Polymorphism; VDR, Vitamin D Receptor. 986 
 987 
 988 
 
Author   
 
Year 
 
Country 
 
Participants 
 
Gene 
 
SNP 
 
Significance 
Guleryuz et al.  2016  Turkey  136 HT patients and 50 healthy controls  VDR  Taql   
Fok1 
Significant 
NS 
Giovinazzo et al.  2016  Italy  100 newly diagnosed HT patients and 100 
healthy controls 
VDR  Bsml, Apal, Taql  NS 
Djurovic et al.  2015  Serbia  44 female HT patients and 32 healthy controls  VDR  Fok1  P = 0.009 
Inoue et al.  2014  Japan  116 HT patients and 76 controls  VDR  Fok1    P = 0∙0174 
Yazici et al.  2013  Turkey  111 HT patients and 159 healthy controls    VDR  Taq1, Fok1    Significant 
Stefanic et al.  2008  Croatia  145 HT patients and 145 euthyroid controls  VDR  BsmI BB 
BsmI‐TaqI BT haplotype   
BsmI‐TaqI bT haplotype   
BsmI‐ApaI‐TaqI baT haplotypes 
BsmI‐ApaI‐TaqI BaT variants   
Pc = 0.0052 
Pc = 0.0008 
Pc = 0.0004   
Pc = 0.012 
Pc = 0.0012   
Lin et al.  2006  China  109 HT patients and 90 healthy controls  VDR  Fok1  P = 0.0458 
Yang & Xiong  2008  China  171    HT patients and 172 healthy controls  CYP27B1 
 
CYP27B1 promoter (‐1260) C/A  P < 0.05 
Lopez et al.  2004  Germany  139 HT Patients and 320 healthy controls    CYP27B1  CYP27B1 intron 6 (+2838) C/T   
CYP27B1 promoter (‐1260) C/A   
P = 0.0058 
P = 0.0173 
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